PDF下载 ( 262 KB)
Advances in the diagnosis and treatment of non-cirrhotic sinusoidal portal hypertension
-
摘要:
肝硬化以外窦性门静脉高压主要涉及肝窦状隙病变,最常见的病因为肝窦阻塞综合征,主要见于造血干细胞移植前化疗预处理及吡咯生物碱中草药治疗,去纤苷是唯一批准的治疗药物;其他病因包括结节再生性增生等,其诊断需借助肝组织学检查,治疗主要针对门静脉高压并发症及潜在原发病。
Abstract:The common causes of non-cirrhotic sinusoidal hypertension were intrahepatic diseases that involves sinusoidal or perisinusoidal space, with sinusoidal obstruction syndrome being a common etiology, which was mainly caused by chemotherapy or radiotherapy prior to hematopoietic stem cell transplantation and pyrrolizidine alkaloid herbal therapy;defibrotide was the only approved drug for this disease. The other causes included nodular regenerative hyperplasia, which were mainly diagnosed by liver pathophysiology;treatment remains largely tar geted at the individual sequalae of portal hypertension and respective potential causes.
-
Key words:
- hypertension, portal /
- diagnosis /
- therapy
-
[1] DA BL, KOH C, HELLER T. Non-cirrhotic portal hypertension[J]. Curr Opin Gastroenterol, 2018, 34 (3) :140-145. [2] FAN CQ, CRAWFORD LM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease) [J]. J Clin Exp Hepatol, 2014, 4 (4) :332-346. [3] WANG X, QI X, GUO X. Tusanqi-related sinusoidal obstruction syndrome in China:A systematic review of the literatures[J]. Medicine (Baltimore) , 2015, 94 (23) :e942. [4] ZHANG JF, LIU B, CHEN CX. Increased chal enge in traditional Chinese medicine containing pyrrolizidine alkaloids-induced hepatic sinusoidal ob-struction syndrome[J]. J Pract Hepatol, 2014, 17 (4) :445-448. (in Chinese) 张骏飞, 刘波, 陈从新.含吡咯烷生物碱的中草药致肝窦阻塞综合征研究进展[J].实用肝脏病杂志, 2014, 17 (4) :445-448 [5] VIGANO L, CAPUSSOTTI L, de ROSA G, et al. Liver resection for colorectal metastases after chemotherapy:Impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival[J]. Ann Surg, 2013, 258 (5) :731-740. [6] NGUYEN-KHAC E, LOBRY C, CHATELAIN D, et al. A reappraisal of chemotherapy-induced liver injury in colorectal liver metastases before the era of antiangiogenics[J]. Int J Hepatol, 2013, 2013:314868. [7] HUBERT C, SEMPOUX C, HUMBLET Y, et al. Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases:Factors predictive of severe SOS lesions and protective effect of bevacizumab[J]. HPB (Oxford) , 2013, 15 (11) :858-864. [8] VREULS CP, OLDE DAMINK SW, KOEK GH, et al. Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer[J]. Br J Cancer, 2013, 108 (3) :676-680. [9] TALLMAN MS, MCDONALD GB, DELEVE LD, et al. Incidence of sinusoidal obstruction syndrome fol owing Mylotarg (gemtuzumab ozogamicin) :A prospective observational study of 482 patients in routine clinical practice[J]. Int J Hematol, 2013, 97 (4) :456-464. [10] MARZANO C, CAZALS-HATEM D, RAUTOU PE, et al. The sig-nificance of nonobstructive sinusoidal dilatation of the liver:Impaired portal perfusion or inflammatory reaction syndrome[J]. Hepatology, 2015, 62 (3) :956-963. [11] TAKAMURA H, NAKANUMA S, HAYASHI H, et al. Severe veno-occlusive disease/sinusoidal obstruction syndrome after deceased-donor and living-donor liver transplantation[J].Transplant Proc, 2014, 46 (10) :3523-3535. [12] MOHTY M, MALARD F, ABECASSIS M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease:Current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT) [J]. Bone Marrow Transplant, 2015, 50 (6) :781-789. [13] SEIFERT C, WITTIG S, ARNDT C, et al. Heparanase polymorphisms:influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation[J]. J Cancer Res Clin Oncol, 2015, 141 (5) :877-885. [14] EFRATI E, ZUCKERMAN T, BEN-AMI E, et al. MTHFR C677T/A1298C genotype:A possible risk factor for liver sinusoidal obstruction syndrome[J]. Bone Marrow Transplant, 2014, 49 (5) :726-727. [15] ROBINSON S, MANN J, VASILAKI A, et al. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model[J]. J Hepatol, 2013, 59 (2) :318-326. [16] ROBINSON S, MANN D, MANAS D, et al. The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome[J]. Br J Cancer, 2013, 109 (9) :2396-2403. [17] EDGAR JA, MOLYNEUX RJ, COLEGATE SM. Pyrrolizidine alkaloids:potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease[J].Chem Res Toxicol, 2015, 28 (1) :4-20. [18] VALLA DC, CAZALS-HATEM D. Sinusoidal obstruction syndrome[J]. Clin Res Hepatol Gastroenterol, 2016, 40 (4) :378-385. [19] CHAO N. How I treat sinusoidal obstruction syndrome[J].Blood, 2014, 123 (26) :4023-4026. [20] GAO H, RUAN JQ, CHEN J, et al. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome[J]. Drug Des Devel Ther, 2015, 9:4861-4868. [21] LEE JH. Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation[J]. Blood Res, 2015, 50 (3) :123-125. [22] SHAO H, CHEN HZ, ZHU JS, et al. Computed tomography findings of hepatic veno-occlusive disease caused by Sedumaizoon with histopathological correlation[J]. Braz J Med Biol Res, 2015, 48 (12) :1145-1150. [23] RICHARDSON PG, TRIPLETT BM, HO VT, et al. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome[J]. Expert Rev Clin Pharmacol, 2018, 11 (2) :113-124. [24] HOPPS SA, BORDERS EB, HAGEMANN TM. Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant:A review of the literature[J]. J Oncol Pharm Practice, 2016, 22 (3) :496-510. [25] YOON JH, MIN WS, KIM HJ, et al. Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT:Is it still reasonable to use t-PA?[J]. Bone Marrow Transplant, 2013, 48 (12) :1562-1568. [26] DIGNAN FL, WYNN RF, HADZIC N, et al. BCSH/BSBMT guideline:Diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation[J]. Br J Haematol, 2013, 163 (4) :444-457. [27] MYERS KC, LAWRENCE J, MARSH RR, et al. High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients[J]. Biol Blood Marrow Transplant, 2013, 19 (3) :492-503. [28] NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, nonalcoholic steatohepatitis (FLINT) :A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385 (9972) :956-965. [29] SCHWABL P, HAMBRUCH E, SEELAND BA, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular re-modelling and sinusoidal dysfunction[J]. J Hepatol, 2017, 66 (4) :724-733. [30] RASZEJA-WYSZOMIRSKA J, WASILEWICZ M, ANDRZEJEWSKA A, et al. Orthotopic liver transplantation (OLTx) in non-cirrhotic portal hypertension secondary to ADAMTS13 deficiency[J]. Prz Gastroenterol, 2016, 11 (1) :56-58. [31] HOPPS SA, BORDERS EB, HAGEMANN TM. Prophylaxis and treatment recommendations for sinusoidal obstruction syndrome in adult and pediatric patients undergoing hematopoietic stem cell transplant:A review of the literature[J]. J Oncol Pharm Practice, 2016, 22 (3) :496-510. [32] BARGE S, GRANDO V, NAULT JC, et al. Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies[J]. Liver Int, 2016, 36 (7) :1059-1066. [33] JHARAP B, van ASSELDONK DP, de BOER NKH, et al. Diagnosing nodular regenerative hyperplasia of the liver is thwarted by low inter-observer agreement[J]. PLoS One, 2015, 10 (6) :e0120299. [34] MEIJER B, SIMSEK M, BLOKZIJL H, et al. Nodular regenerative hyperplasia rarely leads to liver transplantation:A 20-year cohort study in all Dutch liver transplant units[J]. Unit Eur Gastroenterol J, 2017, 5 (5) :658-667. -
本文二维码
计量
- 文章访问数: 314
- HTML全文浏览量: 22
- PDF下载量: 34
- 被引次数: 0
下载:
